DERM
Journey Medical Corporation
There isn't enough reported data to score DERM yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
DERM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Strong |
DERM's revenue and balance sheet are currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
DERM PE Valuation
DERM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
DERM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
DERM has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
DERM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.30 | — |
| Q3 2026 | -$0.18 | +$0.15 |
| Q2 2026 | -$0.22 | +$0.14 |
| Q1 2026 | -$0.37 | $0.00 |
| Q4 2025 | -$0.47 | +$0.25 |
| Q3 2023 | -$0.84 | +$2.61 |
| Q2 2023 | -$2.21 | +$1.83 |
| Q1 2023 | -$2.18 | +$2.73 |
| Q4 2022 | -$1.69 | +$3.11 |
DERM is still losing money, but far less than before: $0.18 per share over the past year, against $4.91 at its worst in early 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over DERM on earnings quality, reporting a profit while its opponent remains loss making.
DERM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +7.6% |
| Q2 2026 | $18.5M | +23% |
| Q1 2026 | $16M | +21% |
| Q4 2025 | $16.1M | +18% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $15M | +1% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $13.6M | -11% |
DERM has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.8% | +5.9 points |
| Q2 2026 | 2.5% | +22 points |
| Q1 2026 | -9.3% | +16 points |
| Q4 2025 | -2.8% | -19 points |
| Q3 2025 | -8.7% | +11 points |
| Q2 2025 | -19% | +0.5 points |
| Q1 2025 | -25% | +52 points |
| Q4 2024 | 16% | +30 points |
DERM's operating margin was −2.8% last quarter, up 5.9 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over DERM on profitability, with a higher operating margin.
DERM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | -$1.1M |
| Q2 2026 | -$1.7M | -$792K |
| Q1 2026 | $2.9M | +$5.7M |
| Q3 2023 | $18.7M | +$26M |
| Q2 2023 | $4M | +$7.3M |
| Q1 2023 | -$6M | -774% |
| Q2 2022 | -$3.3M | +$4.1M |
| Q1 2022 | $884K | -35% |
DERM has burned cash in most quarters: −$5M over the past year, against −$2M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over DERM in the latest year-over-year cash flow comparison.
DERM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +575K shares |
| 1 year | +12% | +3.1M shares |
| 3 years | +33% | +7M shares |
| 5 years | +206% | +18.9M shares |
| Available history | -48% | -26.4M shares |
DERM has 28M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q3 2019 | $163,999 |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over DERM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
DERM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | 0.2x | Very low |
DERM has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
DERM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 7.6 | Oversold |
DERM's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
DERM PE vs Healthcare Sector
DERM has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
DERM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.38 | 18% below |
| 20 week MA | $6.38 | 31% below |
| 50 week MA | $6.65 | 34% below |
| 100 week MA | $6.59 | 33% below |
| 200 week MA | $5.14 | 15% below |
DERM is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over DERM on trend strength, trading above more of its moving averages.
DERM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.50 | $5.70 | -40% |
| 2022 | $5.70 | $1.18 | -79% |
| 2023 | $1.18 | $5.76 | +388% |
| 2024 | $5.76 | $4.17 | -28% |
| 2025 | $4.17 | $7.92 | +90% |
| 2026 YTD | $7.92 | $4.39 | -45% |
DERM's yearly returns have swung widely, from +388% in 2023 to −79% in 2022. It's down 45% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over DERM on returns for 2026, with the stronger performance.